Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback